Lyell Immunopharma Files 8-K
Ticker: LYEL · Form: 8-K · Filed: Dec 10, 2024 · CIK: 1806952
| Field | Detail |
|---|---|
| Company | Lyell Immunopharma, Inc. (LYEL) |
| Form Type | 8-K |
| Filed Date | Dec 10, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, regulatory-filing
TL;DR
Lyell Immunopharma filed an 8-K on 12/10 for a 12/09 event. Details pending.
AI Summary
Lyell Immunopharma, Inc. filed an 8-K on December 10, 2024, reporting an event that occurred on December 9, 2024. The filing is categorized under 'Other Events' and 'Financial Statements and Exhibits'. Specific details regarding the nature of the event or any financial implications are not provided in this excerpt.
Why It Matters
This filing indicates a material event has occurred for Lyell Immunopharma, Inc., requiring public disclosure. Investors should look for further details to understand the event's impact.
Risk Assessment
Risk Level: medium — An 8-K filing signifies a material event, but the lack of specific details in this excerpt necessitates caution until more information is available.
Key Players & Entities
- Lyell Immunopharma, Inc. (company) — Registrant
- 201 Haskins Way (location) — Principal Executive Offices Address
- South San Francisco (location) — City of Principal Executive Offices
- California (location) — State of Principal Executive Offices
- 94080 (location) — Zip Code of Principal Executive Offices
- 650 695-0677 (phone_number) — Registrant's Telephone Number
- December 9, 2024 (date) — Date of earliest event reported
- December 10, 2024 (date) — Date of Report
FAQ
What specific event prompted Lyell Immunopharma, Inc. to file this Form 8-K on December 10, 2024?
The provided excerpt does not specify the exact event, only that it occurred on December 9, 2024, and falls under 'Other Events' and 'Financial Statements and Exhibits'.
What is the primary business of Lyell Immunopharma, Inc. according to the filing?
The filing lists Lyell Immunopharma, Inc.'s Standard Industrial Classification as 'PHARMACEUTICAL PREPARATIONS [2834]'.
Where are Lyell Immunopharma, Inc.'s principal executive offices located?
Lyell Immunopharma, Inc.'s principal executive offices are located at 201 Haskins Way, South San Francisco, California, 94080.
What is the SEC file number for Lyell Immunopharma, Inc.?
The SEC file number for Lyell Immunopharma, Inc. is 001-40502.
When is Lyell Immunopharma, Inc.'s fiscal year end?
Lyell Immunopharma, Inc.'s fiscal year ends on December 31.
Filing Stats: 516 words · 2 min read · ~2 pages · Grade level 11 · Accepted 2024-12-09 21:03:01
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share LYEL The Nasdaq
Filing Documents
- d873794d8k.htm (8-K) — 25KB
- d873794dex991.htm (EX-99.1) — 16KB
- g873794g1209161551105.jpg (GRAPHIC) — 2KB
- 0001193125-24-273688.txt ( ) — 166KB
- lyel-20241209.xsd (EX-101.SCH) — 3KB
- lyel-20241209_lab.xml (EX-101.LAB) — 17KB
- lyel-20241209_pre.xml (EX-101.PRE) — 11KB
- d873794d8k_htm.xml (XML) — 3KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No 99.1 Press Release, dated December 9, 2024, titled "Lyell Presents Positive Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the Treatment of B-cell Lymphoma at the 2024 ASH Annual Meeting." 104.1 Cover Page Interactive Data File, formatted in inline XBRL.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Lyell Immunopharma, Inc. Date:December 9, 2024 By: /s/ Matthew Lang Matthew Lang Chief Business Officer